Background The cytokine interleukin (IL)-1 plays a pivotal role in immune-mediated
disorders, particularly in autoinflammatory diseases. Targeting this cytokine proved to be …

Interleukin-1 (IL-1) is the prototypical inflammatory cytokine: two distinct ligands (IL-1α and IL-
1β) bind the IL-1 type 1 receptor (IL-1R1) and induce a myriad of secondary inflammatory …

Background The interleukin-1 (IL-1) mediated systemic autoinflammatory diseases,
including the cryopyrin-associated periodic syndromes (CAPS), tumour necrosis factor …

Abstract Interleukin-1 (IL-1) is a highly active pro-inflammatory cytokine that lowers pain
thresholds and damages tissues. Monotherapy blocking IL-1 activity in autoinflammatory …

The inflammasome is a molecular platform formed by activation of an innate immune pattern
recognition receptor seed, such as NLRP3. Once activated, NLRP3 recruits the adapter ASC …

IL-1 is a master cytokine of local and systemic inflammation. With the availability of specific
IL-1 targeting therapies, a broadening list of diseases has revealed the pathologic role of IL …

Background Interleukin-1 is pivotal in the pathogenesis of systemic juvenile idiopathic
arthritis (JIA). We assessed the efficacy and safety of canakinumab, a selective, fully human …

An expanding spectrum of acute and chronic non‐infectious inflammatory diseases is
uniquely responsive to IL‐1β neutralization. IL‐1β‐mediated diseases are often called “auto …

Autoinflammatory diseases are characterised by fever and systemic inflammation, with
potentially serious complications. Owing to the rarity of these diseases, evidence-based …

Objective To evaluate the response to treatment of autoinflammatory diseases from an
international registry and an up-to-date literature review. Methods The response to treatment …